AAV Vector for Persistent Anti-Nicotine Antibody Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current strategies for treating nicotine addiction, including anti-nicotine vaccines, have shown limited effectiveness with high recidivism rates and variable antibody production, necessitating alternative compositions and methods to prevent or treat nicotine addiction.
Innovation Solution
An adeno-associated virus (AAV) vector is developed to encode an antibody that binds to nicotine or its analogs, inducing an immune response in mammals, thereby reducing nicotine's addictive effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional anti-nicotine vaccines are used, then an immune response against nicotine is induced, but the antibody production varies significantly among individuals and recidivism rates remain high
Solution Approach 1:
The patent uses adeno-associated virus (AAV) vectors as intermediaries to deliver nicotine-conjugate compositions directly into the body. The AAV vector acts as a mediator that carries the genetic instructions for producing anti-nicotine antibodies, ensuring consistent and persistent antibody production across different individuals, thereby resolving the variability issue of traditional vaccines
Solution Approach 2:
The patent modifies the chemical parameters of nicotine by conjugating it to carrier molecules (such as proteins or polymers) to create immunogenic compositions. This parameter change transforms nicotine from a small, non-immunogenic molecule into a large, immunogenic complex that elicits a strong and consistent immune response, addressing the reliability and consistency problem
2Reliability
If nicotine is conjugated to carrier molecules to induce immune response, then anti-nicotine antibodies are generated, but the complexity of vaccine formulation increases
Solution Approach 1:
The patent employs universal carrier molecules that can conjugate with nicotine through standardized chemical reactions. These carriers serve multiple functions: they provide the necessary immunogenicity, enable consistent antibody production, and simplify formulation by using a single platform for different nicotine derivatives, thereby reducing overall formulation complexity while maintaining reliability
3Reliability
If high levels of anti-nicotine antibodies are produced, then smoking cessation success increases, but the variability in antibody levels among participants reduces overall effectiveness
Solution Approach 1:
The patent incorporates feedback mechanisms through the use of AAV vectors that provide persistent, long-term expression of anti-nicotine antibodies. The viral vector integrates into the host genome and continuously produces antibodies at stable levels, creating a self-regulating system that maintains consistent antibody quantities over time, thereby ensuring reliable smoking cessation outcomes across different individuals
Data Source
AI summary
The invention is directed to an adeno-associated virus (AAV) vector which comprises a nucleic acid sequence encoding an antibody or antigen binding fragment that binds to nicotine or a nicotine analog. The invention also is directed to a composition comprising the AAV vector and methods of using the AAV vector to induce an immune response against nicotine in a mammal.